- Home
- COMM vs ETNB Comparison
COMM vs ETNB Comparison
Compare COMM & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COMM
- ETNB
- Stock Information
- Founded
- COMM 1976
- ETNB 2018
- Country
- COMM United States
- ETNB United States
- Employees
- COMM N/A
- ETNB N/A
- Industry
- COMM Radio And Television Broadcasting And Communications Equipment
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- COMM Technology
- ETNB Health Care
- Exchange
- COMM Nasdaq
- ETNB Nasdaq
- Market Cap
- COMM 1.8B
- ETNB 1.5B
- IPO Year
- COMM 2013
- ETNB 2019
- Fundamental
- Price
- COMM $16.02
- ETNB $8.87
- Analyst Decision
- COMM Hold
- ETNB Strong Buy
- Analyst Count
- COMM 5
- ETNB 10
- Target Price
- COMM $12.38
- ETNB $27.22
- AVG Volume (30 Days)
- COMM 6.5M
- ETNB 1.4M
- Earning Date
- COMM 08-04-2025
- ETNB 08-07-2025
- Dividend Yield
- COMM N/A
- ETNB N/A
- EPS Growth
- COMM N/A
- ETNB N/A
- EPS
- COMM 3.34
- ETNB N/A
- Revenue
- COMM $4,751,500,000.00
- ETNB N/A
- Revenue This Year
- COMM $27.35
- ETNB N/A
- Revenue Next Year
- COMM $9.07
- ETNB N/A
- P/E Ratio
- COMM $4.80
- ETNB N/A
- Revenue Growth
- COMM 20.87
- ETNB N/A
- 52 Week Low
- COMM $2.94
- ETNB $4.16
- 52 Week High
- COMM $16.61
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- COMM 69.17
- ETNB 43.45
- Support Level
- COMM $15.19
- ETNB $8.46
- Resistance Level
- COMM $16.53
- ETNB $9.47
- Average True Range (ATR)
- COMM 0.61
- ETNB 0.46
- MACD
- COMM -0.25
- ETNB -0.02
- Stochastic Oscillator
- COMM 64.88
- ETNB 33.33
About COMM CommScope Holding Company Inc.
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center, and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center, and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services, and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. The company's operating segments are: Connectivity and Cable Solutions (CCS), Networking, Intelligent Cellular and Security Solutions (NICS), and Access Network Solutions (ANS).
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).